Company news
Vistagen Therapeutics, Inc. news in 2019
Vistagen Therapeutics, Inc.'s news releases, calls and decks from 2019, newest first.
VistaGen and Baylor College of Medicine Announce Successful Results of First-Step Target Engagement Study with VistaGen's AV-101 Focused on Treating Suicidal Ideation in Veterans
December 18, 2019
U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder
December 9, 2019
VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder
November 13, 2019
VistaGen Therapeutics Reports Fiscal 2020 Second Quarter Financial Results and Provides Pipeline Overview
November 6, 2019
VistaGen Therapeutics Expands European Patent Protection for AV-101 for Treatment of Depression and Dyskinesia associated with Levodopa Therapy for Parkinson's Disease
October 27, 2019
VistaGen Therapeutics Announces Last Patient Completes Dosing in the ELEVATE Phase 2 Clinical Study of AV-101 for Major Depressive Disorder
October 7, 2019
VistaGen Therapeutics Achieves Target Patient Enrollment in the ELEVATE Study of AV-101 as an Adjunctive Treatment for Major Depressive Disorder
August 14, 2019
Decks in 2019
- Investor Presentation (December 2019)
Investor deck · 47 slides · Dec 27, 2019
- Investor Presentation (October 2019)
Investor deck · 44 slides · Oct 9, 2019
- Investor Presentation (August 2019)
Investor deck · 42 slides · Aug 16, 2019
- Investor Presentation (May 2019)
Investor deck · 45 slides · May 2, 2019
- Cowen and Company 39th Annual Health Care Conference (March 2019)
Conference · 36 slides · Mar 14, 2019
- Investor Presentation (January 2019)
Investor deck · 34 slides · Jan 11, 2019